还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

( S- z2 N8 o" [4 S( t                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

% \- d4 B7 L1 L可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

7 S* ?7 B; U0 t3 m: Y6 x6 g1 ]8 ~
Sub-category:
Molecular Targets


7 e  ]" {9 O! i9 MCategory:
- S" j! Q' G$ n# ]/ k  l$ v8 ~Tumor Biology
( {# _: _- Q4 d# B( ^! q

Meeting:
2011 ASCO Annual Meeting

/ z" V% y! ]3 d  e, X3 M
Session Type and Session Title:
Poster Discussion Session, Tumor Biology

9 j3 [3 G' ~; ?9 P1 E0 p" _
$ ]) [/ u/ H) vAbstract No:
  m5 N+ P  n8 ^0 e. R2 Y10517

8 H: x/ ^' X7 e6 X) A1 V
3 `4 O8 `8 b" W# dCitation:
) t. P% i6 e7 h, J* r1 \$ t: kJ Clin Oncol 29: 2011 (suppl; abstr 10517)
" z$ G9 `6 P% L/ R( H9 N
  s( P: q0 u- J* M* _
8 Y* d4 _' e0 m7 t: v$ FAuthor(s):
7 e& [" O8 Y. f: \* L) U! LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

, C/ t) `3 a6 n, b3 \

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

Abstract:


Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
! I  F' B5 u7 C$ g

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

0 y% g: a# r8 A4 d( H化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
. V- Q, {) l: w, f: U2 ?ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
- @  D! l: _. ~. {- n* P9 Y& l
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊